HIV-1 Vpr-mediated G2 cell cycle arrest is dependent on the interaction of Vpr with an E3 ubiquitin ligase that contains damage-specific DNA binding protein 1 (DDB1), Cullin 4A (Cul4A), DDB1 and Cul4-associated factor 1 (DCAF1), and Rbx1. Vpr is thought to associate directly with DCAF1 in the E3 ubiquitin ligase complex although the exact interaction pattern of the proteins in the complex is not completely defined. The Vpr of SIVagm induces G2 arrest of cognate African Green Monkey (AGM) cells but not human cells. The molecular mechanism by which SIVagm Vpr exhibits its species-specific function remained unknown.
Physical interaction of proteins in the E3 ubiquitin ligase complex was assessed by co-immunoprecipitation followed by western blotting. In addition, co-localization of the proteins in cells was investigated by confocal microscopy. The cell cycle was analyzed by propidium iodide staining and flow cytometry. DNA damage response elicited by Vpr was evaluated by detecting phosphorylation of H2AX, a marker for DNA damage response.
We show that RNAi knock-down of DCAF1 prevented the co-immunoprecipitation of DDB1 with HIV-1 Vpr while DDB1 knock-down did not influence the binding of Vpr to DCAF1. HIV-1 Vpr mutants with a L64P or a R90K mutation maintained the ability to associate with DCAF1 but did not appear to be in a complex with DDB1. SIVagm Vpr associated with AGM DCAF1 and DDB1 while, in human cells, it binds to human DCAF1 but hardly binds to human DDB1, resulting in the reduced activation of H2AX.
The identification of Vpr mutants which associate with DCAF1 but only poorly with DDB1 suggests that DCAF1 is necessary but the simple binding of Vpr to DCAF1 is not sufficient for the Vpr association with DDB1-containing E3 ligase complex. Vpr may interact both with DCAF1 and DDB1 in the E3 ligase complex. Alternatively, the interaction of Vpr and DCAF1 may induce a conformational change in DCAF1 or Vpr that promotes the interaction with DDB1. The ability of SIVagm Vpr to associate with DDB1, but not DCAF1, can explain the species-specificity of SIVagm Vpr-mediated G2 arrest.
VprDCAF1DDB1SIVagm Vpr species-specificity
The Vpr accessory protein is encoded by all lentiviruses but its role in virus replication and pathogenesis is not well understood. Vpr is related by amino acid sequence to the Vpx accessory protein which is encoded by SIVmac and HIV-2. Both Vpr and Vpx are packaged into virions through an interaction with p6 region of HIV Gag [1, 2], suggesting a role in the post-entry process of virus replication. Vpr is not required for virus replication in activated CD4+ T cells but enhances the ability of the virus to infect macrophages [3, 4]. Vpr-deleted SIVmac replicates in Rhesus macaques but tends to revert back to the wild-type, suggesting an important role of this accessory protein in pathogenesis [5, 6]. While several functions have been proposed for Vpr such as nuclear import of the preintegration complex, transactivation of viral genes, dysregulation of cellular gene expression, and impairment of mitochondrial functions [7–19], the most widely accepted feature of Vpr function is its ability to induce G2 cell cycle arrest [20, 21].
Vpr induces G2 cell cycle arrest through its association with the E3 ubiquitin ligase CRL4-DCAF1, a complex that consists of the damage-specific DNA binding protein 1 (DDB1), Cullin 4A (Cul4A), the DDB1 and Cul4-associated factor 1 (DCAF1) and Rbx1 [22–28]. DCAF1 is identical to Vpr binding protein (VprBP) that was previously identified [29, 30]. The amino- and carboxy-terminal regions of Cul4A are responsible for its interaction with DDB1 and Rbx1, respectively. The adaptor DDB1 links Cul4A to a variety of substrate specificity subunits, DCAFs. Many DCAFs identified so far contain specific WDXR motifs [31–34] and the WDXR motif in DCAF1 has been reported to be necessary for the association both with DDB1 and Vpr . The region of Vpr required for binding to DCAF1 was mapped to the leucine-rich motif within the third alpha-helix domain of Vpr . A Vpr mutant, VprQ65R, which is mutated at 65th amino acid residue in this motif, lost the binding to DCAF1 and the ability to arrest cell cycle at G2 phase . In previous reports, the association of Vpr with DCAF1 and DDB1 was examined by co-immunoprecipitation using several Vpr mutants and the results indicated that the binding to DCAF1 fully coincided with the association with DDB1 for all tested mutants [22–24, 27]. From these results, Vpr association with DDB1 is thought to be indirectly mediated by simple binding of Vpr to DCAF1.
SIVmac Vpx also contains the carboxy-terminal alpha helix that is conserved in Vpr. Mutation of the conserved glutamine Q76 residue in this motif, which is corresponding to the Q65 residue of Vpr, disrupts the binding of Vpx to DCAF1, suggesting that Vpx uses the conserved helix domain for interaction with DCAF1 in a manner similar to Vpr [25, 35]. By interacting with the CRL4-DCAF1 E3 ligase complex, Vpx targets sterile alpha motif domain- and HD domain-containing protein 1 (SAMHD1) for proteasomal degradation to counteract the SAMHD1-mediated lentivirus restriction [36, 37]. A recent report resolved the crystal structure of protein complex comprising SIVsm Vpx, the WD40 domain of DCAF1, and the carboxy-terminal region of SAMHD1 .
Molecular mechanism by which Vpr induces G2 arrest remains unresolved. In particular, a cellular target(s) of the Vpr-CRL4-DCAF1 E3 ligase have not been identified. It has been reported that Vpr activates the DNA damage sensing protein, ataxia telangiectasia mutated and Rad3-related protein (ATR), resulting in the phosphorylation of several proteins including Chk1 and histone 2A variant X (H2AX) [39–43]. A significant portion of Vpr appears to colocalize with the phopshorylated-form of H2AX (γH2AX) in the nucleus [39, 44]. The current model for the Vpr-meidated G2 arrest is that Vpr binds to the CRL4-DCAF1 complex through DCAF1 to recruit a yet unknown target on the E3 ligase and the recruited target is subsequently ubiquitinated and degraded, resulting in activation of ATR followed by G2 cell cycle arrest [22–28]. It was recently reported that untimely activation of the SLX4 complex is involved in the Vpr-mediated G2 arrest .
SIVagm also encodes the vpr gene and SIVagm Vpr induces G2 cell cycle arrest in cognate African green monkey (AGM) cells but not in human cells while the Vpr of SIVmac induces G2 cell cycle arrest of monkey cells as well as human cells [46, 47]. The molecular basis of the species-specificity is still unanswered. In addition to the G2 cell cycle arrest, SIVagm Vpr targets SAMHD1 in AGM cells for proteasomal degradation .
While it is clear that Vpr or Vpx forms a complex with DCAF1 in the CRL4-DCAF1 E3 ubiquitin ligase, the interaction among these proteins in the ligase complex are not completely defined. Here we show that point mutants of HIV-1 Vpr that maintain their ability to interact with DCAF1 do not associate with the CRL4 E3 ubiquitin ligase, suggesting that simple binding of Vpr to DCAF1 is distinguishable from the association with DDB1 in the E3 ligase. SIVagm Vpr expressed in human cells readily associated with human DCAF1 but only poorly with human DDB1 while it interacted both with AGM DCAF1 and AGM DDB1 in AGM cells. The species-specific dysfunction of SIVagm Vpr in inducing G2 arrest in human cells may therefore be caused by its failure to properly associate with DDB1 in the CRL4 E3 ubiquitin ligase.
Vpr interaction with the CRL4-DCAF1 complex is dependent upon DCAF1
Vpr is thought to associate with the CRL4-DCAF1 E3 ubiquitin ligase by binding directly to DCAF1 [22–28] as shown in Figure 1A where Vpr binding to DCAF1 is necessary and sufficient for the association. To evaluate this model, we knocked-down DCAF1 or DDB1 and tested whether this affected the ability of Vpr to associate with the CRL4-DCAF1 complex. For this, we transfected HeLa cells with siRNA against DCAF1 or DDB1. A day later, the cells were transfected with pcHA-Vpr, which is an expression vector for HIV-1 Vpr tagged with HA (HA-Vpr). After another two days culture, Vpr was immunoprecipitated with anti-HA MAb and coimmunoprecipitated DCAF1 and DDB1 were detected on an immunoblot. The results showed that the DCAF1 and DDB1 siRNAs knocked-down their respective targets about 80% as compared to a control siRNA which had no effect (Figure 1B). Knock-down of DCAF1 decreased the amount of DDB1 that associated with Vpr. In contrast, knock-down of DDB1 did not affect the amount of DCAF1 associated with Vpr. We also noticed that knock-down of DDB1 caused a small reduction (about 40%) in the steady-state level of DCAF1. This reduction was reproduced with another DDB1 siRNA that targeted a different site on the mRNA (data not shown). The dependence of Vpr on DCAF1 for its association with DDB1 and the lack of dependence of Vpr on DDB1 for the association with DCAF1 suggest that Vpr interacts directly with DCAF1 which mediates the association with DDB1. These results are consistent with the recent model (Figure 1A) showing that DCAF1 is necessary for the association of Vpr with DDB1 in the CRL4 E3 ligase complex.
HIV-1 Vpr point mutants that bind DCAF1 but poorly bind to DDB1
If Vpr binding to DCAF1 which is bound to DDB1 is critical for the Vpr-induced G2 cell cycle arrest, Vpr mutants that are defective in G2 arrest might fail to bind to DCAF1 and not associate with the E3 ubiquitin ligase complex. Vpr mutants that fall into this category include Q65R and H71R [24, 27]. To further test whether mutants that are functionally deficient in arresting cell cycle also fail to bind DCAF1, we evaluated additional mutant Vpr proteins, VprL64P and VprR90K, that have been reported to be defective in inducing G2 arrest [26, 49]. In addition, we also used a VprR90D mutant in which the charge at amino acid R90 was changed. We transfected 293 T cells with Flag-DCAF1 and HA-Vpr or HA-Vpr mutant expression vectors and tested the possible association of expressed proteins by coimmunoprecipitation. In our experiments we found that the addition of exogenous DCAF1 helped to increase the steady-state levels of the transfected Vprs. We believe that this is because DCAF1 binding is required to stablize the proteins in the cell and that the cell does not contain sufficient endogenous DCAF1 to bind the exogenously experssed Vpr proteins. VprL64P was expressed well and co-immunoprecipitated DCAF1 to a similar extent as wild-type Vpr did (Figure 2A). Unexpectedly, VprL64P co-immunoprecipitated only a small amount of DDB1. VprQ65R is defective for DCAF1 binding  and was therefore used as a control. Using this mutant, we confirmed that VprQ65R did not bind to DCAF1 and DDB1 (Additional file 1: Figure S1), confirming the western blot results are reliable. VprR90K and VprR90D were stably expressed and coimmunoprecipitated DCAF1 although VprR90K coimmunoprecipitated less DDB1 compared to wild-type Vpr, a phenotype similar to that of VprL64P (Figure 2B). VprR90D, a nonconservative mutant, retained the ability to coimmunoprecipitate DDB1. To evaluate the ability of VprR90D to arrest the cell cycle at G2 phase, we analyzed the cell cycle profile of the transfected cells. Exogenous expression of DCAF1 led to similar expression levels of Vpr and Vpr mutants (Additional file 2: Figure S2B). We found that VprR90D induced G2 cell cycle arrest while VprR90K did not (Additional file 2: Figure S2A). These activities are consistent with the association of Vpr mutants with DDB1.
Vpr induces the degradation of uracil N glycosylase (UNG2) [26, 50]. UNG2 is a natural substrate for the CRL4-DCAF1 ligase. Although the targeting of UNG2 is not the cause of Vpr-mediated G2 cell cycle arrest , Vpr is thought to recruit UNG2 to the E3 ligase for degradation [50–52]. To determine whether the mutated Vpr proteins induced UNG2 degradation, we cotransfected 293 T cells with HA-UNG2 and the mutated Vpr expression vectors, and evaluated the steady-state level of UNG2 by immunoblot analysis (Figure 2C and D). VprR90K did not induce UNG2 degradation while VprR90D maintained this function, supporting the idea that VprR90K does not associate well with the CRL4-DCAF1 ligase and is not functional. These findings are not easily compatible with the conventional model (Figure 1A) in which direct binding of Vpr to DCAF1 is sufficient for the interaction of Vpr with DDB1. These results also suggest that Vpr may interact with both DCAF1 and DDB1 in the CRL4-DCAF1 E3 ubiquitin ligase to mediate its function and the two binding sites can be genetically dissociated.
The species specificity of SIVagm Vpr is caused by inefficient association with DDB1 in human cells
SIVagm Vpr has been found to induce G2 arrest in African green monkey (AGM) but not in human cells [46, 47]. To confirm the species-specificity of SIVagm Vpr, human 293 T and AGM-derived COS cells were transfected with SIVagm Vpr or SIVmac Vpr expression vector and the cell cycle profile was analyzed by flow cytometry. In 293 T cells, SIVmac Vpr induced G2 arrest but SIVagm Vpr did not (Figure 3A). On the other hand, both SIVmac and SIVagm Vpr induced G2 arrest in COS cells (Figure 3B). These findings confirmed the species-specificity of SIVagm Vpr. To determine whether the specificity is due to species-specific interaction with DCAF1 and DDB1, we tested whether SIVagm Vpr form a complex with DCAF1 and DDB1 in AGM but not human cells. For this, we transfected 293 T and COS cells with SIVmac or SIVagm Myc-Vpr expression vector with (for 293 T cells) or without (for COS cells) Flag-DCAF1 expression vector. We then immunoprecipitated Myc-Vpr and determined the amount of associated DCAF1 and DDB1 by immunoblot analysis. In human cells, SIVmac Vpr coimmunoprecipitated DCAF1 and DDB1 while SIVagm Vpr coimmunoprecipitated DCAF1 but only inefficiently coimmunoprecipitated DDB1 (Figure 3C), a phenotype that was similar to VprL64P. In AGM cells, SIVagm and SIVmac Vpr coimmunoprecipitated DCAF1 and DDB1 (Figure 3D). SIVmac Vpr was expressed at lower levels than SIVagm Vpr but the amount of immunoprecipitated DCAF1 in the samples was similar, suggesting that SIVmac Vpr may bind to DCAF1 more efficiently than SIVagm Vpr. The decreased expression of Myc-tagged SIVmac Vpr was likely not due to protein instability since it pulled-down DDB1 as efficiently as did the highly expressed SIVagm Vpr in COS cells. Thus, in human cells, SIVagm Vpr fails to interact efficiently with complexes that contain DDB1 and does not induce G2 arrest. In AGM cells, SIVagm Vpr and SIVmac Vpr associate with DCAF1 and DDB1, and induce G2 arrest. These results suggest that the species-specificity of SIVagm Vpr-induced G2 arrest is caused by the specificity with which SIVagm Vpr associates with the CRL4 E3 ubiquitin ligase but not due to its specificity with DCAF1.
SIVagm Vpr does not associate efficiently with DDB1 and induces less of a DNA damage response
We next compared the affinity of VprR90K and SIVagm Vpr to DDB1 in human cells. We cotransfected 293 T cells with the respective HA-Vpr expression vector along with Flag-DCAF1 expression vector. Vpr proteins were immunoprecipitated by anti-HA MAb and DCAF1 and DDB1 in the immunoprecipitates were evaluated (Figure 4A). All Vpr proteins including wild type HIV-1 Vpr coimmunoprecipitated DCAF1 at similar efficiency while VprR90K and SIVagm Vpr coimmunoprecipitated less DDB1 as compared to wild type HIV-1 Vpr. Furthermore, the result also showed that the association of DDB1 with SIVagm Vpr is less efficient than that with VprR90K which lost the ability to target UNG2 for proteasomal degradation (Figure 2C).
To further test whether SIVagm Vpr has the reduced association with the CRL4-DCAF1 complex, we cotransfected HeLa cells with HIV-1 or SIVagm HA-Vpr expression vector and assessed the colocalization of Vpr protein with DDB1 by confocal microscopy. Vpr binds to chromatin and forms nuclear foci [39, 44]. To visualize Vpr foci, we permeabilized the transfected cells with Triton X100-containing buffer and fixed them. As expected, DDB1, HIV-1 Vpr, and SIVagm Vpr foci were present in the nucleus (Figure 4B). A fraction of the Vpr foci colocalized with DDB1 dot-like signals. We quantified the extent of co-localization by determining the percentage of Vpr foci that were also positive for DDB1 (Figure 4C). The results showed that HIV-1 Vpr colocalized with DDB1 in a higher number of foci than did SIVagm Vpr.
We also anlayzed colocalization of VprR90K with DDB1. As expected, VprR90K colocalized with DDB1 less frequently compared than wild-type Vpr (Additional file 3: Figure S3), confirming its inefficient association with DDB1. The amount of Vpr colocalized with DDB1 was higher than that in Figure 4C, perhaps as a result of stabilization of the protein by DCAF1. Because we detected less association of SIVagm Vpr with DDB1, we tested whether SIVagm Vpr enhances UNG2 degradation. As for VprR90K, SIVagm Vpr failed to induce the degradation of UNG2 (Additional file 4: Figure S4), a finding that is consistent with the idea that SIVagm Vpr does not associate efficiently with DDB1.
Vpr induces a DNA damage response in the cell, which can be detected by phosphorylation of H2AX . The response is initiated through the association of Vpr with the CRL4-DCAF1 ligase. The phosphorylated form of H2AX, γH2AX, forms nuclear γH2AX foci . If SIVagm Vpr associates inefficiently with CRL4, then it should induce fewer γH2AX foci. To test this, we transfected HeLa cells with HIV-1 or SIVagm HA-Vpr expression vector and then counted the number of γH2AX foci in the Vpr-expressing cells (Figure 5A and B). The results showed that SIVagm Vpr induced fewer γH2AX foci than did HIV-1 Vpr. These results were confirmed by immunoblot analysis which showed that Vpr led to an increase in the cellular concentration of γH2AX and that the increase was less pronounced in SIVagm Vpr-expressing cells than HIV-1 Vpr-expressing cells (Additional file 5: Figure S5). Taken together, these data suggest that SIVagm Vpr associates less efficiently with human DDB1 in the CRL4-DCAF1 complex and induces a weaker DNA damage response, resulting in the species-specific deficiency in G2 cell cycle arrest.
Our results suggest that the interaction of Vpr with DCAF1 is necessary but not sufficient for Vpr function with respect to G2 cell cycle arrest and UNG2 degradation. The configuration of the Vpr-CRL4-DCAF1 E3 ubiquitin ligase complex is more complicated than previously thought since our findings showed that some Vpr point mutants are able to bind DCAF1 but appear not to interact well with the CRL4-DCAF1 complex. In addition, SIVagm Vpr, which has species-specificity in inducing G2 arrest, similarly binds to human DCAF1 but does not associate well with the CRL4-DCAF1 complex in human cells.
In support of the previously predicted direct interaction of Vpr with DCAF1, knock-down of DDB1 had no effect on the association of Vpr with DCAF1. Conversely, Vpr did not co-immunoprecipitate DDB1 when DCAF1 was knocked-down with its siRNAs, supporting the idea that DCAF1 is required for the association of Vpr with DDB1. To our knowledge, none of Vpr point mutants that have previously been analyzed were found to associate with DCAF1 but not with DDB1 [22–24, 27]. In this study, we found that VprL64P and VprR90K maintained the ability to interact with DCAF1 but only weakly interacted with DDB1. A possible explanation for our findings was that the Vpr point mutants might have failed to localize to the nucleus, as this would have allowed for an interaction with DCAF1 but not with CRL4 which is in the nucleus. However, we found that the mutated Vpr proteins actually localized to the nucleus and their localization was not significantly affected by the overexpression of DCAF1 (data not shown), although overexpression of DCAF1 has been reported to relocalize Vpr to the cytoplasm . Furthermore, the cellular distribution pattern of the Vpr mutants was similar to that of wild-type Vpr in all experimental conditions of this study. Also, the localization of DCAF1 or DDB1 to the nucleus was not affected by wild-type or mutated Vpr (data not shown). Therefore, it is unlikely that the cellular localization pattern of these proteins causes the reduced binding of Vpr mutants to DDB1. Both Vpr point mutants, VprL64P and VprR90K, were defective in inducing G2 cell cycle arrest, suggesting that Vpr must associate both with DCAF1 and DDB1 to function. Similar to HIV Vpr point mutants, SIVagm Vpr did not induce G2 arrest and had inefficient association with DDB1 despite binding to DCAF1 in human cells. These results further suggest that the binding of Vpr to DCAF1 is not sufficient for the interaction of Vpr with DDB1 in CRL4 E3 ligase complex that mediates the biological function of Vpr.
Our findings suggest that the association of Vpr with DDB1 is accomplished by an additional step(s) beyond the simple binding of Vpr to DCAF1. It is clear that Vpr interacts with DCAF1 but it is possible that it additionally interacts with DDB1, thereby strengthening the complex. The affinity of Vpr for DDB1 alone is not sufficient to be detected in the absence of DCAF1 but may still contribute to the stability of the complex. It is possible that L64 and R90 residues of Vpr are directly involved in formation of the binding interface for this interaction. Alternatively, the interaction with DCAF1 may induce a conformational alteration in Vpr that allows binding to DDB1. Paramyxovirus simian virus 5 and hepatitis B virus encode proteins that bind to DDB1 in CRL4 through an alpha-helical motif [55, 56]. Vpr is composed of three alpha-helix domains with flexible elements at both ends that could similarly bind DDB1. L64 and R90 residues may act as a binding interface after the conformational change or may be required for the proper conformational change itself. In this model, DCAF1 binding to Vpr is a prerequisite for the association with DDB1. Another hypothesis is that binding of Vpr to DCAF1 may change the DCAF1 conformation to allow tighter binding to DDB1. Crystallographic analyses may help to better define these interactions.
UNG2 is degraded by CRL4-DCAF1 E3 ubiquitin ligase in the absence of Vpr  and Vpr enhances this process. VprR90K was defective for UNG2 degradation most likely because it failed to associate with DDB1. Alternatively, VprR90K could inhibit Vpr-independent UNG2 degradation by sequestering DCAF1 from DDB1-containing CRL4 complexes. In either case, inefficient association with DDB1 could contribute to the failure to degrade UNG2. The inability of VprR90K to degrade UNG2 is inconsistent with a previous report  in which VprR90K caused dose-dependent degradation of UNG2. The reason for this difference is not clear, but could be caused by the addition of the exogenous DCAF1 to stabilze the Vpr proteins in our studies.
We have shown that SIVagm Vpr associates weakly with DDB1 in human cells and the inefficient binding correlates with its inability to induce G2 arrest. SIVagm replicates well in some types of human cell , as Vpr is not necessary for virus replication in T cells. However, the inefficient interaction of SIVagm Vpr with DDB1 could affect virus replication in cell-types such as macrophages where Vpr is thought to play a role.
SIVmac and SIVagm Vpr are only about 30% homologous to HIV-1 Vpr yet interact with the CRL4-DCAF1 complex, highlighting the importance of the E3 ubiquitin ligase for Vpr function. The interaction was species-specific in that SIVagm associated with DCAF1 and DDB1 in AGM cells but only with DCAF1 in human cells. Consistent with this, SIVagm Vpr induced G2 arrest in AGM cells but not in human cells. It remains unclear why SIVagm Vpr fails to associate with DDB1 in human cells. Differences in amino acid sequence of AGM and human DDB1 may cause the species-specific interaction. Alternatively, the interaction of SIVagm Vpr with DDB1 may require unidentified cofactors which are differentially expressed in AGM and human cells.
Finally, our findings suggest that analyses of Vpr mutants should determine whether they interact both with DDB1 and DCAF1, as both interactions play a role in function. The related lentivirus accessory protein, Vpx, also associates with the CRL4-DCAF1 ligase and the interaction is required to induce the degradation of the host restriction factor SAMHD1. It will be of interest to determine whether analogous mutations can be identified in Vpx such that DCAF1 binding is retained but interaction with the E3 ubiquitin ligase complex is affected.
HIV-1 Vpr interacts with DCAF1 and DDB1 to induce G2 arrest, a property that is conserved in SIV Vpr. Identification of Vpr point mutants that bind to DCAF1 but only weakly to DDB1 suggests that binding of Vpr to DCAF1 is not sufficient for the formation of Vpr-CRL4-DCAF1 E3 ligase complex and the formation is more complicated processes than previously thought. The species-specificity of SIVagm Vpr in inducing G2 arrest is caused by its failure to associate with DDB1 in human CRL4 and subsequent less efficient activation of DNA damage response. The species-specificity of SIVagm Vpr highlights adaptations that the virus has made to replicate in its natural host species.
Amino-terminal hemagglutinin (HA)-tagged Vpr expression vectors pcHA-Vpr and pcVprL64P, HA-tagged UNG2 expression vector pcUNG2, myc-tagged SIV Vpr expression vectors pcVpr.agm and pcVpr.mac, and DCAF1/VprBP expression system including pFSZ2-VprBP-FH, pcRev, and pcTat plasmids have been previously described [26, 29]. SIVagm Vpr sequence in pcVpr.agm was derived from the SIVagm.tan. pEGFP-C1 (Clontech) was used in cell cycle analysis. To construct HA-tagged SIV Vpr expression vector, agm Vpr cDNA was amplified using primers 5′-GGGGATATCATGGCAGAAGGAAGAGATTCCAGG-3′ and 5′-GGGCTCGAGCTATGCAAGTCCTGGAGGAGGCTCTC-3′ from pcVpr.agm template. The amplicon was digested with EcoR-V and Xho-I and cloned into the pcHA-Vpr cleaved with Eco-RV and Xho-I. Expression vectors for VprR90K, VprR90D, and VprQ65R were generated by PCR-based site-directed mutagenesis of pcHA-Vpr. All vectors were confirmed by nucleotide sequence analysis.
Transfection and immunoblot analysis
Cells were cultured in DMEM supplemented with 10% fetal bovine serum in a CO2 incubator at 37°C. For transfections, the cells were seed and transfected the next day using Lipofectamine 2000 (Invitrogen). Cell lysates were prepared using buffer containing 0.5% NP40, 10 mM Tris pH 8.0, 150 mM NaCl, and 2 mM EDTA supplemented with protease inhibitor cocktail III (Calbiochem). Lysates were cleared by centrifugation at 10,000 g for 10 min and the protein concentration was determined by Bradford assay. Lysate (10 μg) was separated by SDS-PAGE and transferred to an Invitrolon PVDF membrane (Invitrogen). The membrane was blocked with 5% non-fat milk in PBS with 0.05% Tween 20 (PBST) and probed with anti-HA MAb 16B12 (1:2,000) (Covance) for 1 h. The membrane was washed with PBST and incubated with ImmunoPure biotin-conjugated goat anti-mouse IgG (1:20,000) (Pierce) for 1 h. As a loading control, the membrane was stained with anti-βtubulin MAb (1:1,000) (Sigma). The filters were treated with Dylight 680-conjugated streptavidin (Pierce) for 30 min and the proteins were detected and quantified on an Odyssey Imager (Li COR). Primary antibodies used for immunoblot analysis following immunoprecipitation were anti-myc MAb 9E10 (1:1,000) (Covance), anti-DCAF1 antibody (1:5,000) (Shanhaigenomics), anti-Flag MAb M2 (1:1,000) (Sigma), anti-HA 3 F10 MAb (1:1000) (Roche), anti-DDB1 MAb (1:1,000) (Zymed), anti-DDB1 antibody C-2 (1:500) (Santa Cruz), anti-HA MAb 16B12, and anti-βtubulin MAb. In some cases horseradish peroxidase (HRP)-conjugated secondary antibodies (Invitrogen) were used and the signals were detected using Luminata Forte Western HRP substrate (Millipore) and LAS1000plus or ImageQuant LAS 4010 systems (Fuji Film and GE healthcare).
HeLa cells (1 × 105) were transfected with 100 pmol of siRNA (Dharmacon) using Lipofectamine 2000. After 24 hours, the cells were transfected again with 1 μg of pcHA-Vpr. After an additional 2 days, the cells were lysed in IP lysis buffer (1% NP40, 50 mM Tris pH 7.5, 150 mM NaCl, and 2 mM EDTA) supplemented with protease inhibitor cocktail for immunoprecipitation analysis. siRNA target sequences were: DCAF1, 5′-GGAGGGAAUUGUCGAGAAUUU-3′ (DCAF1-1) and 5′-CGGAGUUGGAGGAGGACGAUU-3′ (DCAF1-2); DDB1, 5′-CCUGUUGAUUGCCAAAAAC-3′. The siCONTOROL#3 (Dharmacon) was used as a control siRNA.
293 T cells were seeded into 6-well plates (1 × 105/well) and COS cells (1 × 106) were seeded into 10 cm dishes. The cells were transfected at the following day and two days posttransfection, the cells were lysed in 500 μl of IP lysis buffer. The lysates were clarified by centrifugation for 10 min at 10,000 g and precleared with protein-G sepharose. A portion of the cleared lysate was retained for immunoblot analysis and the remainder was incubated with anti-HA MAb 16B12, anti-HA MAb 3 F10, or anti-myc MAb 9E10 antibody bound to protein-G sepharose for 2 h at 4°C. The samples were washed five times with IP lysis buffer and resuspended in SDS-PAGE sample buffer for immunoblot analysis.
HeLa cells (1 × 105) were grown on a 35 mm glass bottom dish (Matsunami) and transfected with 0.3 μg of pcHA-Vpr expression plasmid. The transfected cells were fixed with 2% paraformaldehyde in PBS for 15 min and permeabilized with 0.1% triton X-100 for 5 min at room temperature. After blocking with 0.5% BSA in PBS for 30 min, the cells were incubated with anti-HA 3 F10 MAb and anti-γH2AX (Abcam) antibodies for 16 hours at 4°C followed by incubation with fluorescent-labeled secondary antibodies. The cells were visualized with a BZ-8000 (KEYENCE) microscope. For colocalization analysis, the transfected cells were permeabilized with 0.05% triton X-100 and fixed in 2% paraformaldehyde. After blocking with 0.5% BSA, the cells were incubated with anti-HA 3 F10 MAb and anti-DDB1 (Abcam) antibodies, and then stained with fluorescent-labeled secondary antibodies. The cells were imaged on a Zeiss LSM510 Meta laser scanning confocal microscope (Zeiss). The secondary antibodies used are Alexa Fluor 488-conjugated goat anti-rat IgG (H + L) and Alexa Fluor 594 goat anti-rabbit IgG (H + L) (Invitrogen).
Cell cycle analysis
Cells were cotransfected with Vpr expression vectors and pEGFP-C1 vectors. Two days posttransfection, the cells were fixed in cold 75% ethanol, washed with PBS and treated with 0.5 mg/ml RNase A for 30 min. The cells were then stained with 0.05 μg/ml propidium iodide for 30 min and analyzed by flow cytometry in that the GFP+ cells were gated to focus on those that were successfully transfected. The data were analyzed using FlowJo 8.5.2 software (Tree star).
The damage-specific DNA binding protein 1
African green monkey
ATM and Rad3-related protein
DDB1-and CUL4-associated factor 1
Vpr binding protein
Aterile alpha motif domain- and HD domain-containing protein 1
Histone 2A variant X.
We thank Dr. Ling-Jun Zhao for DCAF1 expression vector, pFSZ2-VprBP-FH. The work was funded by grants from the National Institutes of Health (AI067059), and supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 23790510, Grant-in-Aid for Young Scientists (B), and JSPS KAKENHI Grant Number 25460573, Grant-in-Aid for Scientific Research (C).
Department of Microbiology, New York University School of Medicine
Department of Immunology, Kinki University Faculty of Medicine
Cohen EA, Dehni G, Sodroski JG, Haseltine WA: Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 1990, 64:3097–3099.PubMed CentralPubMed
Paxton W, Connor RI, Landau NR: Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 1993, 67:7229–7237.PubMed CentralPubMed
Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman R: Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 1994, 200:623–631.PubMedView Article
Connor RI, Chen BK, Choe S, Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935–944.PubMedView Article
Gibbs JS, Lackner AA, Lang SM, Simon MA, Sehgal PK, Daniel MD, Desrosiers RC: Progression to AIDS in the absence of a gene for vpr or vpx. J Virol 1995, 69:2378–2383.PubMed CentralPubMed
Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Hunsmann G, Muller J, Muller-Hermelink H, Fuchs D, Wachter H, Daniel MM, Desrosiers RC, Fleckenstein B: Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol 1993, 67:902–912.PubMed CentralPubMed
Cohen EA, Terwilliger EF, Jalinoos Y, Proulx J, Sodroski JG, Haseltine WA: Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr 1990, 3:11–18.PubMed
Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A 1994, 91:7311–7315.PubMed CentralPubMedView Article
Hoshino S, Konishi M, Mori M, Shimura M, Nishitani C, Kuroki Y, Koyanagi Y, Kano S, Itabe H, Ishizaka Y: HIV-1 Vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency. J Leukoc Biol 2010, 87:1133–1143.PubMedView Article
Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin P, Metivier D, Lenoir C, Geuskens M, Vieira HL, Loeffler M, Belzacq AS, Briand JP, Zamzami N, Edelman L, Xie ZH, Reed JC, Roques BP, Kroemer G: Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 2001, 193:509–519.PubMed CentralPubMedView Article
Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, Costantini P, Druillennec S, Hoebeke J, Briand JP, Irinopoulou T, Dauqas E, Susin SA, Cointe D, Xie ZH, Reed JC, Roques BP, Kroemer G: The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000, 191:33–46.PubMed CentralPubMedView Article
Kitayama H, Miura Y, Ando Y, Hoshino S, Ishizaka Y, Koyanagi Y: Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol 2008, 82:2528–2542.PubMed CentralPubMedView Article
Muthumani K, Hwang DS, Choo AY, Mayilvahanan S, Dayes NS, Thieu KP, Weiner DB: HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 2005, 17:103–116.PubMedView Article
Poon B, Chen IS: Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J Virol 2003, 77:3962–3972.PubMed CentralPubMedView Article
Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA: HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 2010, 115:1354–1363.PubMed CentralPubMedView Article
Venkatachari NJ, Majumder B, Ayyavoo V: Human immunodeficiency virus (HIV) type 1 Vpr induces differential regulation of T cell costimulatory molecules: direct effect of Vpr on T cell activation and immune function. Virology 2007, 358:347–356.PubMedView Article
Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ: Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 1995, 270:25564–25569.PubMedView Article
Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, Brunetta E, Mavilio D, Planelles V, Barker E: HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog 2009, 5:e1000613.PubMed CentralPubMedView Article
Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS: The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 1995, 69:6304–6313.PubMed CentralPubMed
Rogel ME, Wu LI, Emerman M: The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 1995, 69:882–888.PubMed CentralPubMed
Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA: HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 2007, 3:e85.PubMed CentralPubMedView Article
DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V: HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 2007, 4:57.PubMed CentralPubMedView Article
Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, Florens L, Washburn MP, Skowronski J: Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A 2007, 104:11778–11783.PubMed CentralPubMedView Article
Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, Margottin-Goguet F: HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 2007, 6:182–188.PubMedView Article
Schrofelbauer B, Hakata Y, Landau NR: HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci U S A 2007, 104:4130–4135.PubMed CentralPubMedView Article
Tan L, Ehrlich E, Yu XF: DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 2007, 81:10822–10830.PubMed CentralPubMedView Article
Wen X, Duus KM, Friedrich TD, de Noronha CM: The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 2007, 282:27046–27057.PubMedView Article
Zhang S, Feng Y, Narayan O, Zhao LJ: Cytoplasmic retention of HIV-1 regulatory protein Vpr by protein-protein interaction with a novel human cytoplasmic protein VprBP. Gene 2001, 263:131–140.PubMedView Article
Zhao LJ, Mukherjee S, Narayan O: Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein. J Biol Chem 1994, 269:15577–15582.PubMed
Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N: Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 2006, 443:590–593.PubMed
He YJ, McCall CM, Hu J, Zeng Y, Xiong Y: DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev 2006, 20:2949–2954.PubMed CentralPubMedView Article
Higa LA, Wu M, Ye T, Kobayashi R, Sun H, Zhang H: CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol 2006, 8:1277–1283.PubMedView Article
Jin J, Arias EE, Chen J, Harper JW, Walter JC: A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 2006, 23:709–721.PubMedView Article
Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J: Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474:658–661.PubMed CentralPubMedView Article
Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M: SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474:654–657.PubMed CentralPubMedView Article
Schwefel D, Groom HC, Boucherit VC, Christodoulou E, Walker PA, Stoye JP, Bishop KN, Taylor IA: Structural basis of lentiviral subversion of a cellular protein degradation pathway. Nature 2014, 505:234–238.PubMedView Article
Lai M, Zimmerman ES, Planelles V, Chen J: Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol 2005, 79:15443–15451.PubMed CentralPubMedView Article
Nakai-Murakami C, Shimura M, Kinomoto M, Takizawa Y, Tokunaga K, Taguchi T, Hoshino S, Miyagawa K, Sata T, Kurumizaka H, Yuo A, Ishizaka Y: HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene 2007, 26:477–486.PubMedView Article
Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V: Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 2003, 278:25879–25886.PubMedView Article
Zimmerman ES, Chen J, Andersen JL, Ardon O, Dehart JL, Blackett J, Choudhary SK, Camerini D, Nghiem P, Planelles V: Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol 2004, 24:9286–9294.PubMed CentralPubMedView Article
Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V: Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol 2006, 80:10407–10418.PubMed CentralPubMedView Article
Belzile JP, Abrahamyan LG, Gerard FC, Rougeau N, Cohen EA: Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest. PLoS Pathog 2010, 6:e1001080.PubMed CentralPubMedView Article
Laguette N, Bregnard C, Hue P, Basbous J, Yatim A, Larroque M, Kirchhoff F, Constantinou A, Sobhian B, Benkirane M: Premature activation of the SLX4 complex by Vpr Promotes G2/M arrest and escape from innate immune sensing. Cell 2014, 156:134–145.PubMedView Article
Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, Chen IS: Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol 1996, 70:2516–2524.PubMed CentralPubMed
Stivahtis GL, Soares MA, Vodicka MA, Hahn BH, Emerman M: Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J Virol 1997, 71:4331–4338.PubMed CentralPubMed
Lim ES, Fregoso OI, McCoy CO, Matsen FA, Malik HS, Emerman M: The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 2012, 11:194–204.PubMed CentralPubMedView Article
Selig L, Benichou S, Rogel ME, Wu LI, Vodicka MA, Sire J, Benarous R, Emerman M: Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J Virol 1997, 71:4842–4846.PubMed CentralPubMed
Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR: Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 2005, 79:10978–10987.PubMed CentralPubMedView Article
Ahn J, Vu T, Novince Z, Guerrero-Santoro J, Rapic-Otrin V, Gronenborn AM: HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J Biol Chem 2010, 285:37333–37341.PubMed CentralPubMedView Article
Wen X, Casey Klockow L, Nekorchuk M, Sharifi HJ, de Noronha CM: The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover. PLoS One 2012, 7:e30939.PubMed CentralPubMedView Article
Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM: Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003, 81:123–129.PubMedView Article
Le Rouzic E, Morel M, Ayinde D, Belaidouni N, Letienne J, Transy C, Margottin-Goguet F: Assembly with the Cul4A-DDB1DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation. J Biol Chem 2008, 283:21686–21692.PubMedView Article
Leupin O, Bontron S, Strubin M: Hepatitis B virus X protein and simian virus 5 V protein exhibit similar UV-DDB1 binding properties to mediate distinct activities. J Virol 2003, 77:6274–6283.PubMed CentralPubMedView Article
Li T, Robert EI, van Breugel PC, Strubin M, Zheng N: A promiscuous alpha-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery. Nat Struct Mol Biol 2010, 17:105–111.PubMed CentralPubMedView Article
Daniel MD, Li Y, Naidu YM, Durda PJ, Schmidt DK, Troup CD, Silva DP, MacKey JJ, Kestler HW 3rd, Sehgal PK, King NW, Ohta Y, Hayami M, Desrosiers RC: Simian immunodeficiency virus from African green monkeys. J Virol 1988, 62:4123–4128.PubMed CentralPubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.